Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862329 | 1.00 | GCK (0.65) | GCKKCNH2CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1862090 | 0.92 | GCK (0.54) | GCKKCNH2CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1862085 | 0.92 | GCK (0.54) | GCKKCNH2CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1863080 | 0.92 | GCK (0.68) | GCKKCNH2 | |
| SCHEMBL1863079 | 0.92 | GCK (0.68) | GCKKCNH2 | |
| SCHEMBL1858012 | 0.91 | GCK (0.61) | GCKKCNH2CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1858008 | 0.91 | GCK (0.61) | GCKKCNH2CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1859561 | 0.90 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL1859560 | 0.90 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL1862665 | 0.90 | KCNH2 (0.62) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | GCK 2/4885KCNH2 2241/4885CACNA1G 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.